Selected stock price target news of the day - April 9th, 2025

By: Matthew Otto

RPM Reports Lower Q3 FY2025 Results Amid Weather and Currency Headwinds

RPM International reported fiscal 2025 third-quarter revenue of $1.48 billion, falling short of the $1.51 billion consensus estimate and marking a 3.0% year-over-year decline. Net income was $52.0 million, or $0.40 per diluted share, compared to $61.2 million and $0.47 in the prior year. Adjusted diluted EPS came in at $0.35, $0.16 below the analyst consensus of $0.51, and down 32.7% from the prior year. Adjusted EBIT declined 29.0% to $78.2 million. Cash from operating activities reached $91.5 million, supported by a $36 million inventory reduction under the MAP 2025 initiative.

Performance was mixed across segments. Construction Products Group sales declined 4.5%, with adjusted EBIT down 37.9% due to weather-related volume declines and plant consolidation inefficiencies. Specialty Products Group posted a 10.1% drop in sales and a 44.5% decrease in adjusted EBIT, impacted by soft OEM demand and higher operational expenses. Performance Coatings Group sales fell 0.8%, with adjusted EBIT down 7.0% despite strength in fiberglass-reinforced products. Consumer Group sales slipped 0.7%, while adjusted EBIT dropped 16.6%.

Looking ahead, RPM expects consolidated Q4 sales to remain flat with low-single-digit adjusted EBIT growth. Segment forecasts include mid-single-digit sales growth in PCG, flat results for CPG, and low-single-digit declines in SPG and Consumer.

Analysts Lower Price Targets Following Q3 Miss and Soft Outlook

Morgan Stanley analyst Vincent Sinisi maintained an Equal-Weight rating but revised the price target down from $125 to $113.
BMO Capital analyst John McNulty reiterated an Outperform rating while trimming the price target from $154 to $126.
Baird analyst Ghansham Panjabi kept a Neutral stance and dropped the price target from $125 to $110.
JPMorgan analyst Jeffrey Zekauskas lowered the price target to $100.

Which Analyst has the best track record to show on RPM?

Analyst Jeffrey Zekauskas (JPMORGAN) currently has the highest performing score on RPM with 12/12 (100%) price target fulfillment ratio. His price targets carry an average of $1.92 (1.57%) potential upside. RPM International stock price reaches these price targets on average within 89 days.

Apple Supplier Luxshare Considers Global Production Shift to Address U.S. Tariffs

Apple’s supply chain is under renewed pressure as key assembler Luxshare Precision Industry evaluates moving more production outside of China in response to escalating U.S. tariffs. Luxshare Chairwoman Wang Laichun stated that while Luxshare’s direct exports of finished goods to the United States are limited, the new trade barriers have prompted broader strategic reassessments.

Luxshare is in discussions with unnamed customers—widely understood to include Apple—about shifting production for highly automated products to North America, contingent on commercial guarantees. It is also weighing additional investments in Southeast Asia, where it already has a presence, while pausing some China-based plans. Wang emphasized that any relocation would be subject to long-term viability and risk considerations.

Apple, which has exposure to China through its manufacturing partners, faces potential disruptions from shifting global trade dynamics. Luxshare, one of its key suppliers for AirPods and iPhone assembly, operates facilities in Vietnam, Thailand, Malaysia, the U.S., and Mexico. Tariff disparities may influence relocation decisions: products from Vietnam face a 46% tariff, compared to 36% from Thailand and 24% from Malaysia.

Wang noted that unless such differences exceed 10%, Vietnam is unlikely to lose its edge due to its established infrastructure. She also stated that it typically takes 12 to 18 months to build and activate new production lines in existing overseas locations. While Luxshare does not expect to shoulder tariff costs directly, there is concern that downstream customers like Apple may seek price reductions to offset the impact—adding pressure to an already strained supply chain.

Analysts Adjust Ratings as Tariff-Driven Supply Chain Shifts Raise Uncertainty

Jefferies analyst Edison Lee upgraded from Underperform to Hold, though lowered the price target from $202.33 to $167.88.
BofA Securities analyst Wamsi Mohan reiterated a Buy rating and a $250 price target.

Which Analyst has the best track record to show on AAPL?

Analyst Edison Lee (JEFFERIES) currently has the highest performing score on AAPL with 1/1 (100%) price target fulfillment ratio. His price targets carry an average of $-33.41 (-14.17%) potential downside. Apple stock price reaches these price targets on average within 63 days.

CorMedix Posts Preliminary Q1 2025 Results and Increases First-Half Sales Outlook

CorMedix has announced its preliminary, unaudited financial results for the first quarter of 2025. It reported net revenue of $39.0 million and expects adjusted EBITDA to exceed $22.5 million. Cash and cash equivalents as of March 31, 2025, totaled approximately $77.5 million, excluding restricted cash.

These figures reflect stronger-than-anticipated purchasing activity late in the quarter, prompting the company to raise its H1 2025 net sales guidance for existing purchasing customers to a range of $62 million to $70 million. While Q2 net sales are forecasted to be lower than Q1 due to shipment timing.

Looking ahead, CorMedix expects growth in patient adoption and increased implementation across its customer base throughout 2025, with unit shipments in the second half of the year projected to surpass those in the first half. Additionally, patient enrollment for the Phase 3 DefenCath study in Total Parenteral Nutrition (TPN) patients is slated to begin in late April.

CorMedix believes the peak annual sales potential for DefenCath in this population could reach $150 million to $200 million, within a total addressable market of $500 million to $750 million.

Analysts Maintains Rating Amid Q1 Results and Sales Guidance

Needham analyst Serge Belanger reiterated a Buy rating and a $12 price target.

Which Analyst has the best track record to show on CRMD?

Analyst Serge Belanger (NEEDHAM) currently has the highest performing score on CRMD with 11/14 (78.57%) price target fulfillment ratio. His price targets carry an average of $4.84 (67.60%) potential upside. CorMedix stock price reaches these price targets on average within 438 days.